Cargando…
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has no...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947060/ https://www.ncbi.nlm.nih.gov/pubmed/36525084 http://dx.doi.org/10.1007/s00125-022-05851-x |
_version_ | 1784892471461806080 |
---|---|
author | Radlinger, Bernhard Ress, Claudia Folie, Sabrina Salzmann, Karin Lechuga, Ana Weiss, Bernhard Salvenmoser, Willi Graber, Michael Hirsch, Jakob Holfeld, Johannes Kremser, Christian Moser, Patrizia Staudacher, Gabriele Jelenik, Tomas Roden, Michael Tilg, Herbert Kaser, Susanne |
author_facet | Radlinger, Bernhard Ress, Claudia Folie, Sabrina Salzmann, Karin Lechuga, Ana Weiss, Bernhard Salvenmoser, Willi Graber, Michael Hirsch, Jakob Holfeld, Johannes Kremser, Christian Moser, Patrizia Staudacher, Gabriele Jelenik, Tomas Roden, Michael Tilg, Herbert Kaser, Susanne |
author_sort | Radlinger, Bernhard |
collection | PubMed |
description | AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has not been defined yet. In this study we set out to test whether empagliflozin prevents weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance. METHODS: C57Bl/6 mice were fed a western-type diet supplemented with empagliflozin (WDE) or without empagliflozin (WD) for 10 weeks. A standard control diet (CD) without or with empagliflozin (CDE) was used to control for diet-specific effects. Metabolic phenotyping included assessment of body weight, food and water intake, body composition, hepatic energy metabolism, skeletal muscle mitochondria and measurement of insulin sensitivity using hyperinsulinaemic–euglycaemic clamps. RESULTS: Mice fed the WD were overweight, hyperglycaemic, hyperinsulinaemic and insulin resistant after 10 weeks. Supplementation of the WD with empagliflozin prevented these metabolic alterations. While water intake was significantly increased by empagliflozin supplementation, food intake was similar in WDE- and WD-fed mice. Adipose tissue depots measured by MRI were significantly smaller in WDE-fed mice than in WD-fed mice. Additionally, empagliflozin supplementation prevented significant steatosis found in WD-fed mice. Accordingly, hepatic insulin signalling was deteriorated in WD-fed mice but not in WDE-fed mice. Empagliflozin supplementation positively affected size and morphology of mitochondria in skeletal muscle in both CD- and WD-fed mice. CONCLUSIONS/INTERPRETATION: Empagliflozin protects mice from diet-induced weight gain, insulin resistance and hepatic steatosis in a preventative setting and improves muscle mitochondrial morphology independent of the type of diet. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-022-05851-x. |
format | Online Article Text |
id | pubmed-9947060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-99470602023-02-24 Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis Radlinger, Bernhard Ress, Claudia Folie, Sabrina Salzmann, Karin Lechuga, Ana Weiss, Bernhard Salvenmoser, Willi Graber, Michael Hirsch, Jakob Holfeld, Johannes Kremser, Christian Moser, Patrizia Staudacher, Gabriele Jelenik, Tomas Roden, Michael Tilg, Herbert Kaser, Susanne Diabetologia Article AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has not been defined yet. In this study we set out to test whether empagliflozin prevents weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance. METHODS: C57Bl/6 mice were fed a western-type diet supplemented with empagliflozin (WDE) or without empagliflozin (WD) for 10 weeks. A standard control diet (CD) without or with empagliflozin (CDE) was used to control for diet-specific effects. Metabolic phenotyping included assessment of body weight, food and water intake, body composition, hepatic energy metabolism, skeletal muscle mitochondria and measurement of insulin sensitivity using hyperinsulinaemic–euglycaemic clamps. RESULTS: Mice fed the WD were overweight, hyperglycaemic, hyperinsulinaemic and insulin resistant after 10 weeks. Supplementation of the WD with empagliflozin prevented these metabolic alterations. While water intake was significantly increased by empagliflozin supplementation, food intake was similar in WDE- and WD-fed mice. Adipose tissue depots measured by MRI were significantly smaller in WDE-fed mice than in WD-fed mice. Additionally, empagliflozin supplementation prevented significant steatosis found in WD-fed mice. Accordingly, hepatic insulin signalling was deteriorated in WD-fed mice but not in WDE-fed mice. Empagliflozin supplementation positively affected size and morphology of mitochondria in skeletal muscle in both CD- and WD-fed mice. CONCLUSIONS/INTERPRETATION: Empagliflozin protects mice from diet-induced weight gain, insulin resistance and hepatic steatosis in a preventative setting and improves muscle mitochondrial morphology independent of the type of diet. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-022-05851-x. Springer Berlin Heidelberg 2022-12-16 2023 /pmc/articles/PMC9947060/ /pubmed/36525084 http://dx.doi.org/10.1007/s00125-022-05851-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Radlinger, Bernhard Ress, Claudia Folie, Sabrina Salzmann, Karin Lechuga, Ana Weiss, Bernhard Salvenmoser, Willi Graber, Michael Hirsch, Jakob Holfeld, Johannes Kremser, Christian Moser, Patrizia Staudacher, Gabriele Jelenik, Tomas Roden, Michael Tilg, Herbert Kaser, Susanne Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title | Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title_full | Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title_fullStr | Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title_full_unstemmed | Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title_short | Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
title_sort | empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947060/ https://www.ncbi.nlm.nih.gov/pubmed/36525084 http://dx.doi.org/10.1007/s00125-022-05851-x |
work_keys_str_mv | AT radlingerbernhard empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT ressclaudia empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT foliesabrina empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT salzmannkarin empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT lechugaana empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT weissbernhard empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT salvenmoserwilli empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT grabermichael empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT hirschjakob empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT holfeldjohannes empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT kremserchristian empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT moserpatrizia empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT staudachergabriele empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT jeleniktomas empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT rodenmichael empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT tilgherbert empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis AT kasersusanne empagliflozinprotectsmiceagainstdietinducedobesityinsulinresistanceandhepaticsteatosis |